Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 14,147 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: SARS-CoV Infection, Covid19
Interventions: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination); Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 12 Years and older
Enrollment: 33,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 144
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more

Conditions: Type 2 Diabetes Mellitus
Interventions: exenatide, long acting release, exenatide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 16 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 24
States / cities: Encino, California • La Jolla, California • San Diego, California + 21 more

Conditions: Parkinson's Disease
Interventions: GM608, Placebo Comparator; Drug
Lead sponsor: Genervon Biopharmaceuticals, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes
Interventions: Placebo, Survodutide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 71
States / cities: Birmingham, Alabama • Gilbert, Arizona • Paradise Valley, Arizona + 65 more

Conditions: Chronic Low Back Pain
Interventions: ORAVESCENT Fentanyl Citrate; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 17
States / cities: Jonesboro, Arkansas • Bakersfield, California • San Diego, California + 13 more

Conditions: Prader-Willi Syndrome
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 16 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Irvine, California • Gainesville, Florida • Kansas City, Kansas + 2 more

Conditions: Post-Operative Pain
Interventions: VVZ-149 Injections, Placebo; Drug
Lead sponsor: Vivozon, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
Interventions: Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 41
States / cities: Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more

Conditions: Palmar Hyperhidrosis
Interventions: Glycopyrronium cloth, 2.4%, Vehicle; Drug
Lead sponsor: Journey Medical Corporation; Industry
Eligibility: 9 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 7
States / cities: Encinitas, California • Denver, Colorado • Miami, Florida + 4 more

Conditions: Urogential Chlamydia Trachomatis Infection
Interventions: Doxycyline Hyclate tablet, Vibramycin (doxycyline hyclate) capsule; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 19 Years to 45 Years
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 43
States / cities: Birmingham, Alabama • Foley, Alabama • Tucson, Arizona + 38 more

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: Efimosfermin, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 48
States / cities: Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 34 more

Conditions: Obesity and Overweight
Interventions: GZR18, Tirzepatide; Drug
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 20
States / cities: Bessemer, Alabama • Centreville, Alabama • Little Rock, Arkansas + 16 more

Conditions: Brain Contusion
Interventions: BIIB093, Placebo; Drug
Lead sponsor: Remedy Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Iloprost PD-6, Iloprost PD-15; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: Tedisamil sesquifumarate; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Tullahoma, Tennessee

Conditions: Ulcerative Colitis
Interventions: Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 4
States / cities: Orlando, Florida • Topeka, Kansas • Mentor, Ohio

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Tozorakimab 1, Tozorakimab 2, Placebo; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,713 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 46
States / cities: Sheffield, Alabama • Tempe, Arizona • Lincoln, California + 43 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: GSK3862995B, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 10
States / cities: Yuma, Arizona • Hialeah, Florida • Orange City, Florida + 7 more

Conditions: Immunology
Interventions: TPG1, TPG2, TPG3, Placebo; Dietary Supplement
Lead sponsor: Standard Process Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HIV Infections
Interventions: Hepatitis B Vaccine (Recombinant), gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1991
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Nashville, Tennessee

Conditions: Moderate-to-Severe Asthma
Interventions: Anti-GM-CSF Monoclonal Antibody 400mg, Placebo; Biological · Other
Lead sponsor: Humanigen, Inc.; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 33
States / cities: Birmingham, Alabama • Fullerton, California • Granada Hills, California + 27 more

Conditions: Pulmonary Fibrosis
Interventions: placebo, BIBF 1120; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 27
States / cities: Scottsdale, Arizona • San Francisco, California • Santa Barbara, California + 23 more

Conditions: COVID-19
Interventions: Losmapimod oral tablet, Placebo oral tablet; Drug
Lead sponsor: Fulcrum Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Irvine, California • Miami, Florida • Tampa, Florida + 2 more

Conditions: Motion Sickness
Interventions: Scopolamine, Placebo Nasal Gel; Drug · Other
Lead sponsor: Repurposed Therapeutics, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Long Beach, California

Search by objective public record fields.

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Laparoscopic Colorectomy

ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis

Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin

A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension

Intravenous Tedisamil in the Rapid Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm in Female Subjects

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Safety of a Bovine Thymus Nuclear Extract

A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II

Losmapimod Safety and Efficacy in COVID-19

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects